Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Bought by Gilder Gagnon Howe & Co. LLC

Gilder Gagnon Howe & Co. LLC increased its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 12.0% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 326,349 shares of the company's stock after buying an additional 35,009 shares during the quarter. Gilder Gagnon Howe & Co. LLC owned about 0.50% of Kymera Therapeutics worth $13,129,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Blue Trust Inc. boosted its holdings in Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after purchasing an additional 270 shares during the last quarter. KBC Group NV lifted its position in shares of Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after acquiring an additional 752 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Kymera Therapeutics by 95.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,812 shares of the company's stock worth $194,000 after purchasing an additional 2,350 shares in the last quarter. Summit Investment Advisors Inc. raised its stake in Kymera Therapeutics by 9.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock valued at $198,000 after purchasing an additional 406 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Kymera Therapeutics in the fourth quarter worth $251,000.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on KYMR. HC Wainwright boosted their target price on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Stephens reiterated an "overweight" rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Finally, Citigroup initiated coverage on shares of Kymera Therapeutics in a research report on Thursday, March 13th. They issued a "buy" rating and a $52.00 price target on the stock. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $56.36.

Kymera Therapeutics Stock Up 0.7 %

NASDAQ:KYMR traded up $0.26 during mid-day trading on Thursday, hitting $34.53. 206,214 shares of the stock traded hands, compared to its average volume of 554,734. The stock has a market capitalization of $2.24 billion, a price-to-earnings ratio of -14.72 and a beta of 2.22. Kymera Therapeutics, Inc. has a 52 week low of $19.45 and a 52 week high of $53.27. The firm's 50 day moving average is $29.68 and its two-hundred day moving average is $38.40.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The business had revenue of $7.39 million during the quarter, compared to analysts' expectations of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. As a group, research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Activity

In related news, insider Ellen Chiniara sold 2,241 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $68,238.45. Following the completion of the sale, the insider now directly owns 80,085 shares in the company, valued at $2,438,588.25. The trade was a 2.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Jeremy G. Chadwick sold 1,383 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the sale, the chief operating officer now directly owns 67,800 shares of the company's stock, valued at $2,064,510. The trade was a 2.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,659 shares of company stock valued at $324,567. 15.82% of the stock is currently owned by company insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.